Clinical trials: Tauopathies
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Alzheimer's Disease
Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease
In AD, tau protein is abnormally hyperphosphorylated. Significant changes of hyperphosphorylated tau levels in CSF are found in AD patients.
- Trial name
- NCT00800709
- Testing
- Memantine
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Mental Health Center
Alzheimer's Disease (AD), Time Perception
Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease
Perceiving and representing the passage of time allows us to temporally organize perceptions and memories for the coordination of actions, planning, and the mobilization of cognitive processes toward a goal.
- Trial name
- CHRONOS (NCT07341009)
- Testing
- Chronos battery
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Dementia, Agitation
Virtual Reality to Advance Dementia Care and Quality of Life
The goal of this feasibility clinical trial is to learn whether supervised virtual reality (VR) sessions can be safely and practically provided to adults aged 55 years and older with moderate-to-severe dementia who experience…
- Conditions
- Dementia, Agitation, Behavioural and Psychological Symptoms of Dementia, Major Neurocognitive Disorder
- Trial name
- VR-Care (NCT07893678)
- Testing
- Supervised Virtual Reality Sessions
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alzheimer Disease
S-Equol in Alzheimer's Disease 2 Trial
By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity.
- Trial name
- SEAD2 (NCT03101085)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Russell Swerdlow
Down Syndrome, Intellectual Disability
Escalating Doses of Memantine in Down Syndrome (MEDS-123)
Down syndrome (DS) is typically caused by an extra chromosome 21 in the cell nucleus (trisomy 21, or T21). T21 is both the most common cause of genetically defined intellectual disability and the earliest documented cause of…
- Conditions
- Down Syndrome, Intellectual Disability, Alzheimer Dementia (AD)
- Trial name
- NCT07531940
- Testing
- Memantine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Alzheimer's Disease, Frontotemporal Dementia, Behavioral Variant
Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD).
- Trial name
- NetCogBs (NCT03422250)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Alzheimer's Disease
EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer's Disease (AD) in the U.S.
- Trial name
- NCT00230568
- Testing
- Aricept
- Where
- 35 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eisai Inc.
Stroke, Dementia
Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO)
Background: Recent studies have demonstrated that even mild stroke survivors experience residual damage, which persists and in fact increases in subsequent years.
- Conditions
- Stroke, Dementia, Cerebrovascular Disorders, Alzheimer's Disease
- Trial name
- TABASCO (NCT01926691)
- Where
- Israel
- Volunteers
- 575 people
- Sponsor
- Eli Sprecher, MD
Alzheimer Disease
Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
The main objective of this study is to evaluate the effect of 3 months of "Snoezelen-type" multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for patients with Alzheimer's-type…
- Trial name
- SensiCare (NCT01819714)
- Testing
- Multi-sensory supportive care
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Alzheimer's Disease, Mild Cognitive Impairment
The Treatment of High Intensity Transcranial Current Stimulation for Alzheimer's Disease
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive dysfunction and behavioral impairment. It is currently the most common type of dementia in the old age.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT06380725
- Testing
- Transcranial alternating current stimulation(real stimulation)
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Alzheimer Disease, Healthy
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending…
- Trial name
- NCT06657768
- Testing
- LY4006895
- Where
- 13 sites in United States, Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Alzheimer's Disease
SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)
The purpose of this study is to find out if insulin, when administered as a "nasal spray" into the nasal passages, improves memory in adults with mild cognitive impairment (MCI) or Alzheimer's disease.
- Trial name
- SNIFF 120 (NCT00438568)
- Testing
- Regular Insulin
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- University of Washington
Alzheimer's Disease
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic [PK] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of…
- Trial name
- NCT01702480
- Testing
- GSK2981710
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Cognitive Decline, Dementia
MIND Diet Intervention and Cognitive Decline
Phase III randomized controlled trial designed to test the effects of a 3-year intervention of the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) on cognitive decline and brain neurodegeneration among 600…
- Conditions
- Cognitive Decline, Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- MIND (NCT02817074)
- Testing
- MIND Diet, Mild Weight Loss
- Where
- 2 sites in United States
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
PSP - Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- NCT07217665
- Testing
- AADvac1
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Adam Boxer
Alzheimer's Disease
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease
This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.
- Trial name
- Nebula (NCT02471196)
- Testing
- ORM-12741
- Where
- Finland
- Volunteers
- 308 people
- Sponsor
- Orion Corporation, Orion Pharma
Alzheimer Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Purpose: The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography…
- Trial name
- AV151 (NCT00605046)
- Testing
- SPECT scan
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Critical Illness, Delirium
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
Up to 25% of intensive care unit (ICU) survivors experience cognitive impairment comparable in severity to mild Alzheimer's disease and related dementias after hospital discharge.
- Conditions
- Critical Illness, Delirium, Cognitive Impairment, Cognitive Decline
- Trial name
- SLEEP-COG (NCT06411561)
- Testing
- SLEEP + COG, COG, SLEEP
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Washington